Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis

J Hendrikx, MJ de Jonge, J Fransen, W Kievit… - RMD open, 2016 - rmdopen.bmj.com
Patient assessment of disease activity in rheumatoid arthritis (RA) may be useful in clinical
practice, offering a patient-friendly, location independent, and a time-efficient and cost-…

Joint species distribution modelling with the r‐package Hmsc

…, A Lehikoinen, MMJ de Jonge… - Methods in ecology …, 2020 - Wiley Online Library
Joint Species Distribution Modelling (JSDM) is becoming an increasingly popular statistical
method for analysing data in community ecology. Hierarchical Modelling of Species …

Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

J Rodon, I Braña, LL Siu, MJ De Jonge, N Homji… - Investigational new …, 2014 - Springer
Purpose The pan-Class I PI3K inhibitor buparlisib (BKM120) has shown activity in a range
of preclinical cancer models. This first-in-man study was initiated to identify the maximum …

[HTML][HTML] The IRAM 30-m millimeter radio telescope on Pico Veleta, Spain

…, PG Mezger, MJ de Jonge - … (ISSN 0004-6361) …, 1987 - adsabs.harvard.edu
In the Spanish Sierra Nevada near 2900 m altitude, the new 30-m telescope for millimeter
astronomy is now operational. The authors describe the original design features, which …

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

A Sparreboom, MJ De Jonge, P De Bruijn… - Clinical cancer research …, 1998 - AACR
The objective of this study was to determine the metabolic fate and disposition of the
antitumor camptothecine derivative irinotecan (CPT-11). Ten patients with histological proof of …

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

…, HJM Groen, DSW Tan, T Hida, MJ De Jonge… - 2019 - ascopubs.org
9004 Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data
of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) …

Projecting terrestrial biodiversity intactness with GLOBIO 4

…, A Benítez‐López, MMJ de Jonge… - Global Change …, 2020 - Wiley Online Library
Scenario‐based biodiversity modelling is a powerful approach to evaluate how possible
future socio‐economic developments may affect biodiversity. Here, we evaluated the changes …

Life cycle carbon efficiency of Direct Air Capture systems with strong hydroxide sorbents

MMJ de Jonge, J Daemen, JM Loriaux… - International Journal of …, 2019 - Elsevier
Direct Air Capture (DAC) of carbon dioxide (CO 2 ) from ambient air has the potential to combat
climate change. DAC systems capture CO 2 using a sorbent material and compress it for …

[HTML][HTML] TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

…, R Bahleda, AJ Wagner, E Choy, MJ De Jonge… - Nature …, 2016 - nature.com
In tumours that harbour wild-type p53, p53 protein function is frequently disabled by the
mouse double minute 2 protein (MDM2, or HDM2 in humans). Multiple HDM2 antagonists are …

First-in-human phase I study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive …

…, T Fleitas Kanonnikoff, A Cervantes, MJ De Jonge… - Clinical Cancer …, 2016 - AACR
Purpose: A first-in-human phase I study was conducted to characterize safety, efficacy, and
pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized …